Proteomic study of gamma-oryzanol preventive effect on a diet-induced non-alcoholic fatty liver disease model

Autor(es):Mostrar menos -

Siqueira, Juliana Silva ; Garcia, Jessica Leite ; Ferron, Artur Junio Togneri ; Moreto, Fernando ; Sormani, Luis Eduardo ; Costa, Mariane Rovero ; Palacio, Thiago Luiz Novaga ; Nai, Gisele Alborghetti ; Aldini, Giancarlo ; Francisqueti-Ferron, Fabiane Valentini ; Correa, Camila Renata ; D'Amato, Alfonsina

• Tipo de documento: Artigo Científico
• Fonte: JOURNAL OF NUTRITIONAL BIOCHEMISTRY; v. 127, p. 12-pg., 2024-03-18.

Resumo

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease associated with obesity and diabetes prevalence. The use of natural compounds has become an attractive approach to prevent NAFLD and its progression. Gamma-oryzanol (Orz) is a natural compound whose beneficial effects on chronic metabolic diseases have been reported. Therefore, we aimed to investigate the preventive effect of Orz on the hepatic proteome in a diet induced NAFLD model. Wistar rats were randomly distributed into three experimental groups ( n = 6/group) according to the diet received for 30 weeks: Control group, high sugar -fat (HSF) group, and HSF + Orz group. The isolated Orz was added to the chow at the dose of 0.5% (w/w). We evaluated the nutritional profile, characterized the presence of steatosis through histological analysis, triglyceride content in liver tissue and hepatic inflammation. Next, we performed label -free quantitative proteomics of hepatic tissue. Network analysis was performed to describe involved protein pathways. NAFLD induction was characterized by the presence of hepatic steatosis. Orz prevented lipid accumulation. The compound prevented alterations of the hepatic proteome, highlighted by the modulation of lipid metabolism, inflammation, oxidative stress, xenobiotic metabolism, and the sirtuin signaling pathway. It was possible to identify key altered pathways of NAFLD pathophysiology modulated by Orz which may provide insights into NAFLD treatment targets. (c) 2024 Elsevier Inc. All rights reserved. (AU)

• Processo FAPESP: 15/10626-0 - Inter-relação do gama-orizanol e ativação dos receptores Adipo- R1 e Adipo- R2: possível efeito na melhora da função renal associada à obesidade
• Beneficiário: Camila Renata Corrêa
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 22/16108-4 - Panorama ômico e molecular na doença hepática gordurosa não alcoólica (DHGNA): impacto do Gama orizanol
• Beneficiário: Juliana Silva Siqueira
• Modalidade de apoio: Bolsas no Brasil - Doutorado